105 related articles for article (PubMed ID: 26285463)
1. [PERSONALIZED MEDICINE : PHARMACOECONOMIC ASPECTS].
Oruyère O; Reginster JY; Ethgen O
Rev Med Liege; 2015; 70(5-6):339-42. PubMed ID: 26285463
[TBL] [Abstract][Full Text] [Related]
2. Just caring: assessing the ethical and economic costs of personalized medicine.
Fleck LM
Urol Oncol; 2014 Feb; 32(2):202-6. PubMed ID: 24445288
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
O'Donnell JC
Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
[TBL] [Abstract][Full Text] [Related]
4. Personalized medicine policy challenges: measuring clinical utility at point of care.
van Rooij T; Wilson DM; Marsh S
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
[TBL] [Abstract][Full Text] [Related]
5. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
6. Current methodological issues in the economic assessment of personalized medicine.
Annemans L; Redekop K; Payne K
Value Health; 2013; 16(6 Suppl):S20-6. PubMed ID: 24034308
[TBL] [Abstract][Full Text] [Related]
7. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
Frueh FW
Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
[TBL] [Abstract][Full Text] [Related]
8. Economic outcomes and contemporary pharmacy practice.
Reeder CE
Am Pharm; 1993 Dec; NS33(12 Suppl):S3-6. PubMed ID: 8109541
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
Weintraub WS
J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
[TBL] [Abstract][Full Text] [Related]
10. Making personalized medicine more affordable.
Aronson N
Ann N Y Acad Sci; 2015 Jun; 1346(1):81-9. PubMed ID: 25728478
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for performing a pharmacoeconomic analysis.
Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
[TBL] [Abstract][Full Text] [Related]
12. How do we evaluate the economics of health care?
Kumar S; Williams AC; Sandy JR
Eur J Orthod; 2006 Dec; 28(6):513-9. PubMed ID: 17035484
[TBL] [Abstract][Full Text] [Related]
13. Implementation of genomic medicine in a health care delivery system: a value proposition?
Wade JE; Ledbetter DH; Williams MS
Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):112-6. PubMed ID: 24619641
[TBL] [Abstract][Full Text] [Related]
14. Re-engineering drug development: integrating pharmacoeconomic research into the drug development process.
Data JL; Willke RJ; Barnes JR; DiRoma PJ
Psychopharmacol Bull; 1995; 31(1):67-73. PubMed ID: 7675991
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacoeconomic and pharmacogenetic aspects of the implementation of a personalized approach in the treatment of cardiac patients].
Gruzdeva AA; Khokhlov AL; Ilyin MV; Oynotkinova OS
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Aug; 29(Special Issue):1258-1263. PubMed ID: 34792874
[TBL] [Abstract][Full Text] [Related]
17. Key aspects of health system change on the path to personalized medicine.
Downing GJ
Transl Res; 2009 Dec; 154(6):272-6. PubMed ID: 19931192
[TBL] [Abstract][Full Text] [Related]
18. The pharmacoeconomic picture in Saudi Arabia.
Alkhenizan A
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):483-90. PubMed ID: 24953076
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic investigations in intensive care.
Chalfin DB
Curr Opin Crit Care; 2001 Dec; 7(6):460-3. PubMed ID: 11805552
[TBL] [Abstract][Full Text] [Related]
20. Economic incentives for evidence generation: promoting an efficient path to personalized medicine.
Towse A; Garrison LP
Value Health; 2013; 16(6 Suppl):S39-43. PubMed ID: 24034311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
